An evaluation of short-acting β2-agonist prescriptions and associated clinical outcomes in asthma management in Indonesia – the SABINA Indonesia study

Background: Asthma is a chronic inflammatory disease, therefore inhaled corticosteroid (ICS) should be as the cornerstone of asthma treatment. However patients tend to rely on short-acting β2-agonist (SABA) due immediate symptom relief and underuse ICS, thereby undertreating underlying inflammation. As part multi-country SABA use IN (SABINA) III study, we aimed describe prescription patterns asthma-related clinical outcome in Indonesia.Methods: Cross-sectional study (> 12 years old) during August 2019 – January 2020. Disease characteristic, prescribed treatment months before visit, outcomes, were recorded single visit entered into an electronic case report form.Results: Of 219 recruited, mean number canisters was 4 per year. over-prescription (≥ 3 canisters/year) seen 37% patients, greater moderate-to-severe vs mild (40% 17.9%). 47.5% had at least 1 severe exacerbation; 7.3% ≥3 exacerbations, past months. Almost half (40.2%) oral corticosteroids (OCS). Overall, well-, partly, uncontrolled 41.6%, 37.4%, 21%, respectively.Conclusion: occurs approximately one third especially among almost experienced exacerbation previous This highlights public health concern need improve care by aligning with global recommendations including reducing over-reliance Indonesia